Edition:
United Kingdom

Neptune Wellness Solutions Inc (NEPT.TO)

NEPT.TO on Toronto Stock Exchange

5.58CAD
9:00pm BST
Change (% chg)

$-0.31 (-5.26%)
Prev Close
$5.89
Open
$5.90
Day's High
$5.96
Day's Low
$5.51
Volume
136,923
Avg. Vol
383,225
52-wk High
$8.60
52-wk Low
$3.31

Summary

Name Age Since Current Position

John Moretz

2017 Chairman of the Board

Michael Cammarata

2019 Chief Executive Officer, Director

Mario Paradis

2015 Chief Financial Officer

Michel Timperio

2013 Senior Vice President of Sales - Global Sales

Martin Landry

2019 Chief of Corporate Development and Strategy

Pierre Lemieux

Chief Operating Officer of Acasti

Graham Wood

2019 Chief Scientific Officer

Jean-Daniel Belanger

2014 Corporate Secretary and Director - Corporate Affairs

Helene Fortin

58 2018 Director

Harlan Waksal

65 2012 Director

Valier Boivin

2013 Independent Director

Ronald Denis

2014 Independent Director

Adrian Montgomery

2014 Independent Director

Reed Tuckson

67 2013 Independent Director

Jerald Wenker

51 2014 Independent Director

John Ripplinger

IR Contact Officer
» Insider Trading

Biographies

Name Description

John Moretz

Mr. John Moretz serves as Chairman of the Board of Neptune Technologies & Bioressources Inc. Mr. Moretz currently serves as Chief Executive Officer and President of Moretz Marketing, LLC and is Managing Director for Kathy Ireland, LLC. In addition, he is the managing director for various real estate entities, including LaMoe, LLC and Moretz Mills, LLC. Mr. Moretz spent 39 years in the hosiery industry. He served as the Chairman and Chief Executive Officer of Gold Toe Moretz Holdings Corp. and its subsidiaries prior to its acquisition by Gildan Activewear Inc. in 2011. Mr. Moretz also founded Moretz Marketing in 1987 to create and manage lifestyle brands and create licensing opportunities.

Michael Cammarata

Mr. Michael Cammarata is Chief Executive Officer, Director of the Company. Mr. Cammarata is the co-founder of Schmidt's Naturals, now a business unit of Unilever, which has quickly established itself as one of the fastest growing wellness brands. Mr. Cammarata's investment, strategic retail partnerships and deep understanding of digital architecture contributed to breakthrough years for Schmidt's Naturals' from its start-up stage in 2015 to the acquisition by Unilever in 2017. He led Schmidt's Naturals as CEO to exponential growth of the Schmidt's brand in 2018 and 2019, through expansion into distribution and further expanding product lines including hemp derived wellness products domestically and globally.

Mario Paradis

Mr. Mario Paradis is Chief Financial Officer of the Company., effective August 24, 2015. Mr. Paradis was formerly vice president and CFO at Atrium, which was acquired in 2014 by corporations backed by Permira funds in a transaction valued at over $1.1 billion. Prior to this, he held roles of increasingly authority at Aeterna Zentaris, most notably as vice president finance and administration & corporate secretary. Mr. Paradis began his career at PricewaterhouseCoopers, where he successfully held senior positions primarily in audit and tax. Mr. Paradis is a member of the Canadian Chartered Professional Accountants. He holds a bachelor's degree in business, with a specialty in accounting, from Universite du Quebec a Trois-Rivieres.

Michel Timperio

Mr. Michel Timperio is Senior Vice President of Sales - Global Sales of Neptune Technologies & Bioressources Inc. Mr. Michel Timperio obtained a Bachelor degree from Concordia University in 1980 and attended additionnal courses at l’ENAP (National Institute of Public Administration). Mr. Timperio was elected as Chairman of the Board of Neptune in 2000 until 2008. He joined Neptune as a full time employee in September 2010. Prior to joining the Neptune team, Mr. Timperio started his career with Amstrong World Industries as sales representative for Eastern Canada and subsequently with Reicchold Chemicals as regional sales manager in 1982. After earning a young entrepreur loan and scholarship, he started his own distribution business, Specgraphix/Unic in 1985 specializing in the distribution of printing raw material products. During his business endeavours he was the recipient of many sales recognition awards as top sales executives and was also elected as alderman seating on the executive council of one of the largest Montreal suburb, in the city of Longueuil. In 1987, He hosted the first socio-economic summit of one of the largest administrative region in the province of Québec.

Martin Landry

Pierre Lemieux

Graham Wood

Dr. Graham Wood has been appointed as Chief Scientific Officer of the company. May 01, 2019. Dr. Wood, holder of a PhD in neurology and neurosurgery from McGill University, is a distinguished researcher and executive and a recognized leader in the clinical pharmacology of cannabis with experience with combustible, vaping, sublingual, and oral oils and capsules formulations of cannabis. He has conducted over 400 clinical pharmacology studies with companies such as Phoenix International, MDS Pharma, Allied Research and Cetero, and was chief executive officer at Manna Research (a late-phase clinical CRO). He was most recently chief research and development officer at Altasciences, where he led cannabis research.

Jean-Daniel Belanger

Mr. Jean-Daniel Belanger is Corporate Secretary and Director - Corporate Affairs of the Corporation since November 2012 and Corporate Secretary since June 2014. He is in charge of all corporate, governance and securities law matters of the Corporation. He oversees and leads negotiations on corporate and financing matters and is an integral member of the management team, reporting directly to the President and Chief Executive Officer. He holds a law degree from the University de Montréal (2005) and is a member of the Quebec Bar since 2006. Prior to joining the Corporation, Jean-Daniel was a partner in a Montreal securities boutique-firm, where he practiced in the areas of mergers and acquisitions, corporate finance and securities, and general corporate and commercial law.

Helene Fortin

Ms. Helene F. Fortin is Director of the Company. She has been practicing public accounting for more than 30 years. A member of CPA Québec, she lectured in Accounting and Auditing during more than 20 years at many universities in both the undergraduate and graduate levels. She was actively involved from 1982 to 2015 with the Canadian Institute of Chartered Accountants (CPA Canada), on the Interprovincial Board of Evaluators, and with the Auditing and Assurance Standards Board during which time the 36 international standards of auditing were adopted inCanadafrom 2006 to 2009. She has been serving on boards of directors of large public and private corporations since 2003 which provides her with exposure to the best practices within a wide range of organizations, including Loto Québec, a Crown Corporation of the Province of Québec, as Chair of the Board of Directors, UBS Bank (Canada), Institute of Corporate Directors/Quebec, VoiceAge Corporation, and the federal department audit committees of the Public Service Commission and of Agriculture/Agrifood Canada. Former positions include the following Boards: CBC/Radio-Canada, Hydro-Québec, Infrastructure Québec,Concordia Universityand Bellus Health. She is also actively involved with asset management and financing/funding strategies in her role as trustee/advisor for large pension plans, estates, and foundations.

Harlan Waksal

Dr. Harlan W. Waksal, M.D., is Director of Neptune Technologies & Bioressources Inc., since May 23, 2012. Dr. Waksal is a retired physician. Dr. Waksal is the Vice-President, Business and Scientific Affairs at Acasti Pharma Inc. (“Acasti”), the Corporation’s subsidiary. He received his B.A. from Oberlin College and M.D. from Tufts University School of Medicine, and his post graduate training in Internal Medicine and in Pathology. In addition, he did research in immunology at the Weizmann Institute of Science. Dr. Waksal was a founder of Imclone Systems Incorporated; a New York based pharmaceutical company specializing in developing new treatment for various forms of cancer. He served as the Chief Operating Officer and member of the Board of Directors from 1986 until 2001 and as President/CEO from 2001 until 2002. During his tenure, he was responsible for building the scientific and operation infrastructure of the company. Dr. Waksal is the author of over 50 scientific publications and has been the author of multiple patents and patent applications. His current activities are focused on managing various real estate developments and serving on select Board of Directors. Dr. Waksal currently serves on the Boards of the Oberlin College, Senesco Technologies, Inc. He also serves on the Advisory Board of Northern Rivers Funds.

Valier Boivin

Mr. Valier Boivin is an Independent Director of Neptune Technologies & Bioressources Inc., Mr. Valier Boivin holds a bachelor’s degree in Economic and Administrative Sciences (UQAC-1973), a master’s degree in Taxation (Université de Sherbrooke, 1978) and a law degree (Université de Montréal, 1985). Furthermore, he is a member of the “Barreau du Québec” since 1986 and the “Ordre des comptables agréés du Québec” since 1974. He held the position of Professor at the Université du Québec à Chicoutimi until 1978 and then joined the master’s degree in taxation program as Professor, at the Université de Sherbrooke until 1987. Founder (in 1987) of Boivin O’Neil, s.e.n.c., He practices business law. Specialized in Mergers & Acquisitions and corporate financing, Mr. Boivin acts as legal and strategic counsel to many private and public companies. Since January 2009, Mr. Boivin is President of the regional economic intervention fund, FIER Ville-Marie L.P. Mr. Boivin is also socially involved with various professional associations, non-profit organizations and charitable foundations.

Ronald Denis

Dr. Ronald Denis is Independent Director of Neptune Technologies & Bioressources Inc. Dr. Denis was a director of Neptune Technologies & Bioressources Inc. Dr. Ronald Denis has been Chief of Surgery and director of the Trauma Program at Hôpital du Sacré-Coeur in Montréal since 1997. Since 1987, Dr. Denis has also been medical co-director of the Canadian Formula 1 Grand Prix. Dr. Denis sits on several scientific boards and management committees.

Adrian Montgomery

Mr. Adrian Montgomery is an Independent Director of Neptune Technologies & Bioressources Inc., Mr. Montgomery is the Chief Investment Officer of Tuckamore Capital, a publicly-traded company that has invested approximately $700 million in successful private businesses since its inception in 2005. Prior to joining Tuckamore, he headed business development at Rogers Media Inc. Mr. Montgomery is a lawyer and member of the New York State Bar and currently serves on the boards of Epsilon Energy, a TSX-listed Company, and the Toronto East General Hospital Foundation.

Reed Tuckson

Dr. Reed V. Tuckson, M.D., has been appointed as an Independent Director of Neptune Technologies & Bioressources Inc., with effect from 5 November 2013. Dr. Tuckson is currently the Managing Director of Tuckson Health Connections, LLC, a health and medical care consulting business. Previously, Dr. Tuckson served a long tenure as Executive Vice President and Chief of Medical Affairs for UnitedHealth Group, a Fortune 25 health and wellbeing company, which includes the United States largest health insurer and the industry's most comprehensive health services company. Dr. Tuckson is a graduate of Howard University, Georgetown University School of Medicine, and the Hospital of the University of Pennsylvania's General Internal Medicine Residency and Fellowship Programs, where he was also a Robert Wood Johnson Foundation Clinical Scholar studying at the Wharton School of Business. He also serves on the Boards of the American Telemedicine Association, Howard University and Cell Therapeutics Inc., a public corporation.

Jerald Wenker

Mr. Jerald J. Wenker is an Independent Director of Neptune Technologies & Bioressources Inc., Mr. Wenker is currently President and Chief Operating Officer of Dermalogica, a leading professional skin care company based in the United States. Previously, Mr. Wenker was President of Ther-Rx Corporation, the branded division of KV Pharmaceuticals. Prior to Ther-Rx, Mr. Wenker worked at Abbott Laboratories for approximately 15 years where he held several executive roles in such areas as commercial and marketing management, strategic planning, licensing and new business development as well as new product development. Mr. Wenker holds a Master of Science in Marketing from Northwestern University’s J.L. Kellogg Graduate School of Management.

John Ripplinger

Insider Trading

» Full list on Insider Trading